Gemma Aragonès1, Marina Colom-Pellicer1, Carmen Aguilar1, Esther Guiu-Jurado2, Salomé Martínez3, Fàtima Sabench4, José Antonio Porras5, David Riesco5, Daniel Del Castillo4, Cristóbal Richart1,5, Teresa Auguet6,7. 1. Grup de Recerca GEMMAIR (AGAUR) - Medicina Aplicada, Departament de Medicina i Cirurgia, Universitat Rovira i Virgili (URV), Institut d'Investigació Sanitària Pere Virgili (IISPV), 43007, Tarragona, Spain. 2. IFB-Adiposity Diseases, Leipzig University, Liebigstraße 19-21, 04103, Leipzig, Germany. 3. Servei Anatomia Patològica, Hospital Universitari Joan XXIII Tarragona, Mallafré Guasch, 4, 43007, Tarragona, Spain. 4. Servei de Cirurgia, Hospital Sant Joan de Reus, Departament de Medicina i Cirurgia, Universitat Rovira i Virgili (URV), IISPV, Avinguda Doctor Josep Laporte, 2, 43204, Reus, Spain. 5. Servei Medicina Interna, Hospital Universitari Joan XXIII Tarragona, Mallafré Guasch, 4, 43007, Tarragona, Spain. 6. Grup de Recerca GEMMAIR (AGAUR) - Medicina Aplicada, Departament de Medicina i Cirurgia, Universitat Rovira i Virgili (URV), Institut d'Investigació Sanitària Pere Virgili (IISPV), 43007, Tarragona, Spain. tauguet.hj23.ics@gencat.cat. 7. Servei Medicina Interna, Hospital Universitari Joan XXIII Tarragona, Mallafré Guasch, 4, 43007, Tarragona, Spain. tauguet.hj23.ics@gencat.cat.
Abstract
BACKGROUND/ OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) causes a wide spectrum of liver damage, from simple steatosis (SS) to cirrhosis. SS and non-alcoholic steatohepatitis (NASH) cannot be distinguished by clinical or laboratory features. Dysregulation of the gut microbiota is involved in NASH pathogenesis. The aim of this study was to assess the relationship between microbiota-derived metabolites and the degrees of NAFLD; also, to investigate whether these metabolites could be included in a panel of NASH biomarkers. SUBJECTS/ METHODS: We used liquid chromatography coupled to triple-quadrupole-mass spectrometry (LC-QqQ) analysis to quantify choline and its derivatives, betaine, endogenous ethanol, bile acids, short-chain fatty acids and soluble TLR4 in serum from women with normal weight (n = 29) and women with morbid obesity (MO) (n = 82) with or without NAFLD. We used real-time polymerase chain reaction (RT-PCR) analysis to evaluate the hepatic and intestinal expression level of all genes studied (TLR2, TLR4, TLR9, LXRα, SREBP1C, ACC1, FAS, PPARα, CPT1α, CROT, SREBP2, ABCA1, ABCG1 and FXR in the liver; TLR2, TLR4, TLR5, TLR9, GLP-1R, DPP-4, FXR and PPARɣ in the jejunum) in 82 women with MO with normal liver histology (NL, n = 29), SS (n = 32), and NASH (n = 21). RESULTS: Hepatic FAS, TLR2, and TLR4 expression were overexpressed in NAFLD patients. TLR2 was overexpressed in NASH patients. In women with MO with NAFLD, we found upregulation of intestinal TLR9 expression and downregulation of intestinal FXR expression in women with NASH. Circulating TMAO, glycocholic acid and deoxycholic acid levels were significantly increased in NAFLD patients. Endogenous circulating ethanol levels were increased in NASH patients in comparison to those in SS patients. CONCLUSIONS: These findings suggest that the intestine participates in the progression of NAFLD. Moreover, levels of certain circulating microbiota-related metabolites are associated with NAFLD severity and could be used as a "liquid biopsy" in the noninvasive diagnosis of NASH.
BACKGROUND/ OBJECTIVES:Non-alcoholic fatty liver disease (NAFLD) causes a wide spectrum of liver damage, from simple steatosis (SS) to cirrhosis. SS and non-alcoholic steatohepatitis (NASH) cannot be distinguished by clinical or laboratory features. Dysregulation of the gut microbiota is involved in NASH pathogenesis. The aim of this study was to assess the relationship between microbiota-derived metabolites and the degrees of NAFLD; also, to investigate whether these metabolites could be included in a panel of NASH biomarkers. SUBJECTS/ METHODS: We used liquid chromatography coupled to triple-quadrupole-mass spectrometry (LC-QqQ) analysis to quantify choline and its derivatives, betaine, endogenous ethanol, bile acids, short-chain fatty acids and soluble TLR4 in serum from women with normal weight (n = 29) and women with morbid obesity (MO) (n = 82) with or without NAFLD. We used real-time polymerase chain reaction (RT-PCR) analysis to evaluate the hepatic and intestinal expression level of all genes studied (TLR2, TLR4, TLR9, LXRα, SREBP1C, ACC1, FAS, PPARα, CPT1α, CROT, SREBP2, ABCA1, ABCG1 and FXR in the liver; TLR2, TLR4, TLR5, TLR9, GLP-1R, DPP-4, FXR and PPARɣ in the jejunum) in 82 women with MO with normal liver histology (NL, n = 29), SS (n = 32), and NASH (n = 21). RESULTS: Hepatic FAS, TLR2, and TLR4 expression were overexpressed in NAFLD patients. TLR2 was overexpressed in NASH patients. In women with MO with NAFLD, we found upregulation of intestinal TLR9 expression and downregulation of intestinal FXR expression in women with NASH. Circulating TMAO, glycocholic acid and deoxycholic acid levels were significantly increased in NAFLD patients. Endogenous circulating ethanol levels were increased in NASH patients in comparison to those in SS patients. CONCLUSIONS: These findings suggest that the intestine participates in the progression of NAFLD. Moreover, levels of certain circulating microbiota-related metabolites are associated with NAFLD severity and could be used as a "liquid biopsy" in the noninvasive diagnosis of NASH.
Authors: E Naito; Y Yoshida; K Makino; Y Kounoshi; S Kunihiro; R Takahashi; T Matsuzaki; K Miyazaki; F Ishikawa Journal: J Appl Microbiol Date: 2011-02-01 Impact factor: 3.772
Authors: Zobair M Younossi; Rohit Loomba; Quentin M Anstee; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Zachary D Goodman; Naga P Chalasani; Kris V Kowdley; Jacob George; Keith Lindor Journal: Hepatology Date: 2018-07 Impact factor: 17.425
Authors: Laia Bertran; Rosa Jorba-Martin; Andrea Barrientos-Riosalido; Marta Portillo-Carrasquer; Carmen Aguilar; David Riesco; Salomé Martínez; Margarita Vives; Fàtima Sabench; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Int J Mol Sci Date: 2022-07-04 Impact factor: 6.208
Authors: Laia Bertran; Angela Pastor; Marta Portillo-Carrasquer; Jessica Binetti; Carmen Aguilar; Salomé Martínez; Margarita Vives; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Int J Mol Sci Date: 2021-05-15 Impact factor: 5.923
Authors: Teresa Auguet; Laia Bertran; Jessica Binetti; Carmen Aguilar; Salomé Martínez; Fàtima Sabench; Jesús Miguel Lopez-Dupla; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart Journal: Int J Mol Sci Date: 2020-06-11 Impact factor: 5.923
Authors: P León-Mimila; H Villamil-Ramírez; X S Li; D M Shih; S T Hui; E Ocampo-Medina; B López-Contreras; S Morán-Ramos; M Olivares-Arevalo; P Grandini-Rosales; L Macías-Kauffer; I González-González; R Hernández-Pando; F Gómez-Pérez; F Campos-Pérez; C Aguilar-Salinas; E Larrieta-Carrasco; T Villarreal-Molina; Z Wang; A J Lusis; S L Hazen; A Huertas-Vazquez; S Canizales-Quinteros Journal: Diabetes Metab Date: 2020-08-10 Impact factor: 6.041